The introduction of blocking immunotherapy against the programmed death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) has given impressive results and prolonged the survival time of advanced HCC patients [6]. The gene discussed is CD274; the disease is hepatocellular carcinoma.